search
Back to results

Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism

Primary Purpose

Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism

Status
Completed
Phase
Phase 1
Locations
Colombia
Study Type
Interventional
Intervention
Angel Catheter
Sponsored by
BiO2 Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pulmonary Embolism focused on measuring Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Central Line Catheter, Vena Cava Filters

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject is 18 years and older
  2. Be admitted to the hospital

    One of the following two criteria:

  3. Patients with proven deep vein thrombosis (DVT) or pulmonary embolism ( PE), at high risk for pulmonary embolism and under consideration for insertion of a retrievable inferior vena cava (IVC) filter with at least one of the following criteria:

    • Contraindications for anticoagulation
    • Recurrent PE despite adequate anticoagulation
    • Emergency treatment following massive pulmonary embolism
  4. Patients at high risk for developing PE who require but have a temporary or absolute contraindication for prophylaxis with anticoagulation, including:

    • Patients with multiple trauma and active or recent bleeding with contraindications to anticoagulation or that require a temporary stop of anticoagulation
    • severe head injury with coma
    • severe hemorrhagic stroke with coma
    • head injury with a long bone fracture
    • spinal cord injury with paraplegia or quadriplegia
    • multiple (≥2) long bone fractures with pelvic fracture
    • multiple (≥4) long bone fractures
    • Critically ill patients in the Medical or Surgical Intensive Care Unit with high risk of PE that require but are contraindicated for anticoagulation prophylaxis and will benefit from a temporary filter and a central venous access catheter
    • Patients who had recently undergone or are about to undergo a surgical procedure that requires temporary interruption of anticoagulation for Venous Thromboembolism (VTE) and will benefit from a temporary vena cava filter and central

Exclusion Criteria:

  1. Patient is less than 18 years
  2. Patient is pregnant or has a positive serum human chorionic gonadotropin (HCG) pregnancy test at baseline visit
  3. Patient or next legal representative cannot give informed consent
  4. Patients with anticipated survival < 2 days (catastrophic illness)
  5. Body mass index greater than 35
  6. Patient has a pre-existing filter
  7. Participation in another simultaneous interventional medical investigation or interventional trial.
  8. Patient has indications for a permanent filter at the time of the initial evaluation
  9. Patient has an uncontrollable coagulopathy with active bleeding.
  10. Patient with proven endocarditis or bacteremia
  11. Patient has hypersensitivity to any of the components of the Angel™ Catheter, specifically Nitinol
  12. Known acute or chronic thrombotic occlusion of both common femoral veins or iliac veins
  13. Patient with functioning pelvic renal allograft on the only side available for device insertion
  14. Patient who will undergo surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted

Sites / Locations

  • Clinica las Americas
  • Hospital Pablo Tobon Uribe

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Angel Catheter

Arm Description

Outcomes

Primary Outcome Measures

Safety
Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.

Secondary Outcome Measures

Full Information

First Posted
July 25, 2011
Last Updated
April 10, 2013
Sponsor
BiO2 Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT01403090
Brief Title
Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Official Title
A Single Treatment, Open Label, Multicenter, Safety Study of the Angel™ Catheter in Hospitalized Human Subjects With a Temporary Risk of Pulmonary Embolism
Study Type
Interventional

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BiO2 Medical

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The primary endpoint is freedom from serious adverse events (SAE), defined as death, symptomatic pulmonary embolism or major bleeding .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Keywords
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Central Line Catheter, Vena Cava Filters

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Angel Catheter
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Angel Catheter
Intervention Description
The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
Primary Outcome Measure Information:
Title
Safety
Description
Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is 18 years and older Be admitted to the hospital One of the following two criteria: Patients with proven deep vein thrombosis (DVT) or pulmonary embolism ( PE), at high risk for pulmonary embolism and under consideration for insertion of a retrievable inferior vena cava (IVC) filter with at least one of the following criteria: Contraindications for anticoagulation Recurrent PE despite adequate anticoagulation Emergency treatment following massive pulmonary embolism Patients at high risk for developing PE who require but have a temporary or absolute contraindication for prophylaxis with anticoagulation, including: Patients with multiple trauma and active or recent bleeding with contraindications to anticoagulation or that require a temporary stop of anticoagulation severe head injury with coma severe hemorrhagic stroke with coma head injury with a long bone fracture spinal cord injury with paraplegia or quadriplegia multiple (≥2) long bone fractures with pelvic fracture multiple (≥4) long bone fractures Critically ill patients in the Medical or Surgical Intensive Care Unit with high risk of PE that require but are contraindicated for anticoagulation prophylaxis and will benefit from a temporary filter and a central venous access catheter Patients who had recently undergone or are about to undergo a surgical procedure that requires temporary interruption of anticoagulation for Venous Thromboembolism (VTE) and will benefit from a temporary vena cava filter and central Exclusion Criteria: Patient is less than 18 years Patient is pregnant or has a positive serum human chorionic gonadotropin (HCG) pregnancy test at baseline visit Patient or next legal representative cannot give informed consent Patients with anticipated survival < 2 days (catastrophic illness) Body mass index greater than 35 Patient has a pre-existing filter Participation in another simultaneous interventional medical investigation or interventional trial. Patient has indications for a permanent filter at the time of the initial evaluation Patient has an uncontrollable coagulopathy with active bleeding. Patient with proven endocarditis or bacteremia Patient has hypersensitivity to any of the components of the Angel™ Catheter, specifically Nitinol Known acute or chronic thrombotic occlusion of both common femoral veins or iliac veins Patient with functioning pelvic renal allograft on the only side available for device insertion Patient who will undergo surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos Cadavid, MD
Organizational Affiliation
Hospital Pablo Tobon Uribe
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bladimir Gil, MD
Organizational Affiliation
Clinica Las Americas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinica las Americas
City
Medellin
State/Province
Antioquia
Country
Colombia
Facility Name
Hospital Pablo Tobon Uribe
City
Medellin
State/Province
Antioquia
Country
Colombia

12. IPD Sharing Statement

Learn more about this trial

Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism

We'll reach out to this number within 24 hrs